Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
International Biotechnology Trust (LSE:IBT) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
International Biotechnology Trust Liabilities-to-Assets Related Terms
International Biotechnology Trust Liabilities-to-Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Biotechnology Trust Liabilities-to-Assets Chart
LSE:IBT vs VRTX, REGN, MRNA: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, International Biotechnology Trust's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Biotechnology Trust Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Biotechnology Trust's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where International Biotechnology Trust's Liabilities-to-Assets falls into.
International Biotechnology Trust Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Biotechnology Trust (LSE:IBT) has a Liabilities-to-Assets of 0.09 as of Feb. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on International Biotechnology Trust and its competitors.
Is International Biotechnology Trust's Liabilities-to-Assets too high?
International Biotechnology Trust's current Liabilities-to-Assets is 0.09. Overall, International Biotechnology Trust has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does International Biotechnology Trust's Liabilities-to-Assets compare to VRTX and REGN?
International Biotechnology Trust's Liabilities-to-Assets of 0.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on International Biotechnology Trust and its competitors. International Biotechnology Trust's current Liabilities-to-Assets is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Biotechnology Trust stock overvalued right now?
International Biotechnology Trust (LSE:IBT) has a current Liabilities-to-Assets of 0.09. The current Liabilities-to-Assets is 0.09. International Biotechnology Trust's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For International Biotechnology Trust (LSE:IBT), the current Liabilities-to-Assets is 0.09 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
International Biotechnology Trust PLC is an investment trust company. It aims at achieving long-term capital growth by investing in biotechnology and other life sciences companies. It seeks to achieve its objective by investing in a diversified portfolio of companies which has good growth prospects. It focuses on investments in biotechnology companies which are engaged in on drug discovery and development, medical devices companies and healthcare services provider. The invests in various financial instruments such as equities, index-linked securities, debt securities, cash deposits, money market instruments ,and foreign currency exchange transactions. Its revenue comprises of dividend, interest and other income from investment made.
28GF Score
Get the complete analysis for LSE:IBT
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IBT has been successfully added to your 
